Drug treatments for lower urinary tract symptoms secondary to bladder outflow obstruction: Focus on quality of life

Drugs

Volumn 63, Issue 18, 2003, Pages 1947-1962

  MacDonald, Donald ^a   McNicholas, Thomas A ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LISTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALFUZOSIN; DOXAZOSIN; FINASTERIDE; PLACEBO; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

ACUTE KIDNEY FAILURE; AGING; BLADDER NECK STENOSIS; CLINICAL TRIAL; DRUG EFFECT; HEMATURIA; HISTOPATHOLOGY; HUMAN; MORBIDITY; PREVALENCE; PROSTATE HYPERTROPHY; PROSTATE SURGERY; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE FLOW RATE; URINE RETENTION;

ADRENERGIC ALPHA-ANTAGONISTS; HUMANS; MALE; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TESTOSTERONE 5-ALPHA-REDUCTASE; URINARY BLADDER; URINARY BLADDER NECK OBSTRUCTION; URINARY RETENTION; UROLOGIC DISEASES;

EID: 0043239154     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363180-00004     Document Type: Review

References (80)

1. Blanker M, Groeneveld F, Prins A, et al. Strong effects of definition and nonresponse bias on prevalence rates of clinical benign prostatic hyperplasia: the Krimpen study of male urogenital tract problems and general health status. BJU Int 2000; 85 (6): 665-71
2. Chatelian C, Denis L, Foo KT, et al., editors. 5th international consultation on benign prostatic hyperplasia. Plymouth: Plymbridge Distributors Limited, 2001
3. Abrams P. Managing lower urinary tract symptoms in older men. BMJ 1995; 310: 1113-7
4. Boyle P, Maisonneuve P, Steg A. Decrease in mortality from benign prostatic hyperplasia: a major unheralded health triumph. J Urol 1996; 155: 176-80
5. Chisholm GD. Obstructive uropathy: a review of 146 patients with postrenal uraemia. S Afr Med J 1967; 41: 962-4
6. Sells H, Donovan J, Ewings P, et al. The development and validation of a quality of life measure to assess partner morbidity in benign prostatic enlargement. BJU Int 2000; 85: 440-5
7. Hines JEW. Symptom indices in bladder outlet obstruction. BJU Int 1996; 77: 494-501
8. Barry MJ. Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia. Urology 2001; 58 Suppl. 6A: 25-32
9. Kawakami J, Nickel JC. Acute urinary retention and surgery for benign prostatic hyperplasia: the patient's perspective. Can J Urol 1999; 6 (3): 819-22
10. Namasivayan S, Minhas S, Brooke J, et al. The evaluation of sexual function in men presenting with symptomatic benign prostatic hyperplasia. BJU Int 1998; 82 (6): 842-6
11. Green JSA, Holden STR, Ingram P, et al. An investigation of erectile dysfunction in Gwent, Wales. BJU Int 2001; 88: 551-3
12. Feldman HA, Goldstein I, Hatzichchristou D, et al. Impotence and its medical and psychological correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61
13. Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the 'Cologne Make Survey'. Int J Impot Res 2000; 12: 305-11
14. Barry MJ, Fowler FJ, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992; 148: 1549-57
15. Boyarsky S, Jones G, Paulson DF, et al. A new look at bladder neck obstruction by the Food and Drug regulators: guidelines for investigation of benign prostatic hypertrophy. Trans Am Assoc Genitourin Surg 1977; 68: 29-32
16. Madsen PO, Iversen P. A point system for selecting operative candidates. In: Hinman E, editor. Benign prostatic hypertrophy. New York: Springer-Verlag, 1983: 763-5
17. Fowler FJ, Wennberg JE, Timothy RP, et al. Symptom status and quality of life following prostatectomy. JAMA 1988; 259: 3018-22
18. Hald T, Nordling J, Andersen JT, et al. A patient weighted symptom score system in the evaluation of uncomplicated benign prostatic hyperplasia. Scand J Urol Nephrol Suppl 1991; 138: 59-62
19. Donovan JL, Abrams P, Peters TJ, et al. The ICS-'BPH' Study: the psychometric validity and reliability of the ICS male questionnaire. Br J Urol 1996; 77: 554-62
20. Donovan JL, Kay HE, Peters TJ, et al. Using the ICSQoL to measure the impact of lower urinary tract symptoms on quality of life: evidence from the ICS-'BPH' study. Br J Urol 1997; 80: 712-21
21. Frankel SF, Donovan JL, Peters TL, et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol 1998; 51 (8): 677-85
22. Barry MJ, Williford WO, Chang Y, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995; 154: 1770-4
23. Lukacs B, Comet D, Grange JC, et al. Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire. BJU 1997; 80: 722-30
24. Barry MJ, Fowler FJ, O'Leary MP, et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care 1995; 33 Suppl. 4: AS145-55
25. Rosen R, Riley A, Wagner G, et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49 (6): 822-30
26. O'Leary M, Fowler F, Lenderking W, et al. A brief male sexual function inventory for urology. Urology 1995; 46: 697-706
27. Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9
28. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469-71
29. Garraway WM, McKelvie GB, Russell EBAW, et al. Impact of previously unrecognised benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract 1993; 43: 319-21
30. Jolleys JV, Donovan JL, Nachahal K, et al. Urinary symptoms in the community; how bothersome are they? Br J Urol 1994; 74: 551-5
31. McNicholas TA. LUTS suggestive of BOO: what are the current practice patterns? Eur Urol 2001; 39 Suppl. 3: 26-30
32. Simpson RJ, Lee RJ, Garraway WM, et al. Consultation pattern in a community survey of men with benign prostatic hyperplasia. Br J Gen Pract 1994; 44: 449-502
33. Calais de Silva F, Marquis P, Deschaseaux P, et al. Relative importance of sexuality and quality of life in patients with prostatic symptoms: results of an international study. Eur Urol 1997; 31: 272-80
34. Girman CJ, Jacobsen SJ, Tsukamoto T, et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998; 51: 428-36
35. Lee AJ, Garraway WM, Simpson RJ, et al. The natural history of untreated lower urinary tract symptoms in middle-aged and elderly men over a period of five years. Eur Urol 1998; 34: 325-32
36. Jacobsen SJ, Girman CJ, Guess HA, et al. New diagnostic and treatment guidelines for benign prostatic hyperplasia. Arch Intern Med 1995; 155: 477-81
37. Treagust J, Morkane T, Speakman M. Estimating a population's needs for the treatment of lower urinary tract symptoms; what is the extent of the unmet need? J Public Health Med 2001; 23 (2): 141-7
38. Blanker MH, Driessen LF, Bosch JL, et al. Health status and its correlates among Dutch community-dwelling older men with and without lower urogenital tract dysfunction. Eur Urol 2002; 41: 602-7
39. Jacobsen SJ, Girman CJ, Guess HA, et al. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996; 155: 595-600
40. Jacobsen SJ, Jacobsen DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158: 481-7
41. Roberts RO, Jacobsen SJ, Rhodes T, et al. Natural history of prostatism: impaired health states in men with lower urinary tract symptoms. J Urol 1997; 157: 1711-7
42. Girman CJ, Panser LA, Chute CG, et al. Natural history of prostatism: urinary flow rates in a community based study. J Urol 1993; 150: 887-92
43. Lee AJ, Russell EBAW, Garraway WM, et al. Three-year follow-up of a community-based cohort of men with untreated benign prostatic hyperplasia. Eur Urol 1996; 30: 11-7
44. Barry MJ, Fowler Jr FJ, Bin L, et al. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American Urologists. J Urol 1997; 157: 10-5
45. Ball AJ, Feneley RCL, Abrams PH. The natural history of untreated 'prostatism'. Br J Urol 1981; 53: 613-6
46. McConnell JD. Benign prostatic hyperplasia: hormonal treatment. Urol Clin North Am 1995; 22: 387-400
47. Russell DW, Wilson JD. Steroid 5α-reductase: two genes/two enzymes. Annu Rev Biochem 1994; 63: 25-61
48. Berthaut I, Mestayer C, Portois MC, et al. Pharmacological and molecular evidence for the expression of two steroid 5α-reductase isoenzymes in normal and hyperplastic human prostatic cells in culture. Prostate 1997; 32: 155-63
49. Negri-Cesi P, Poletti A, Colciago A, et al. Presence of 5α-reductase isoenzymes and aromatase in human prostate cancer cells and in benign prostatic hyperplastic tissue. Prostate 1998; 34: 283-91
50. Cunha GR, Chung LWK, Shannon JM. Hormone-induced morphogenesis and growth: role of mesenchyme-epithelial interactions. Recent Prog Horm Res 1983; 39: 559-98
51. Cunha GR, Donjacour AA, Cooke PS, et al. The endocrinology and developmental biology of the prostate. Endocr Rev 1987; 8: 338-62
52. Roehrborn C, Andriole G, Boyle P, et al. Effect of the dual 5 alpha-reductase inhibitor dutasteride on endocrine parameters and prostate volume [abstract 417]. Eur Urol Suppl 2002; 1 (1): 107
53. Furuya S, Kumamoto Y, Yokoyama E, et al. Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol 1982; 141: 836-9
54. Caine M, Perlberg S, Meretyk S. A placebo-controlled double-blind trial of phenoxybenzamine in benign prostatic obstruction. Br J Urol 1978; 50: 551-4
55. 1D adrenoreceptors in hyperplastic and non-hyperplastic human prostate. J Urol 1999; 161: 635-40
56. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of α1-adrenoreceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1-13
57. Andersson K-E. The concept of uroselectivity. Eur Urol 1998; 33 Suppl. 2: 7-11
58. Rossi C, Kortmann BBM, Sonke GS, et al. α-blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it. J Urol 2001; 165: 38-41
59. Bruskewitz R, Girman CJ, Fowler J, et al. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. Urology 1999; 54: 670-8
60. Roehrborn CG, Siegel RL. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology 1996; 48: 406-15
61. Gillenwater JY, Conn RL, Chrysant SG, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double blind, placebo-controlled, dose-response multicenter study. J Urol 1995; 154: 110-5
62. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hypertrophy. Urology 1998; 51: 892-900
63. Abrams P, Shulman CC, Vaage S. Tamsulosin, a selective α1c-adrenoreceptor antagonist: a randomised, controlled trial inpatients with benign prostatic 'obstruction' (symptomatic BPH). Br J Urol 1995; 76: 325-36
64. Chapple CR, Wyndaele JJ, Nordling J, et al. Tamsulosin, the first prostate-selective α1 A-adrenoreceptor antagonist: a meta-analysis of two randomised, placebo-controlled, multicenter studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996; 29: 155-67
65. Narayan P, Tewari A, United States 93-01 Study Group. A second phase III multicenter placebo controlled study of two dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 1998; 160: 1701-6
66. Hansen BJ, Flyger H, Mortensen S, et al. Symptomatic outcome of transurethral prostatectomy, alpha-blockade and placebo in the treatment of benign prostatic hyperplasia. Scand J Urol Nephrol 1996; 30: 103-7
67. Buzelin JM, Roth S, Geffriaud-Ricouard C, et al. Efficacy and safety of sustained release alfuzosin 5mg in patients with benign prostatic hypertrophy. Eur Urol 1997; 31: 190-8
68. Roehrborn CG, ALFUS Study Group. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomised placebo-controlled trial. Urology 2001; 58: 953-9
69. Debruyne FMJ, Witjes WP, Fitzpatrick J, et al. The International Terazosin Trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. Eur Urol 1996; 30: 369-76
70. Hillman AL, Schwartz JS, Willian MK, et al. The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Urology 1996; 47: 169-78
71. Lepor H, Williford WO, Barry MJ, et al. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. J Urol 1998; 160: 1358-67
72. Roehrbrn CG, Oesterling JE, Auerbach S, et al. The Hytrin Community Assessment Trail Study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 1996; 47: 159-68
73. Fawzy A, Braun K, Lewis GP, et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154: 105-9
74. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338 (9): 557-63
75. Michel MC, Goepel M. Lower urinary tract symptoms suggestive of benign prostatic obstruction: what's the longterm effectiveness of medical therapies? Eur Urol 2001; 39 Suppl. 3: 20-5
76. Epstein RS, Deverka PA, Chute CG, et al. Validation of a new quality of life questionnaire for benign prostatic hyperplasia. J Clin Epidemiol 1992; 45: 1431-45
77. O'Leary MP. Quality of life and α-blocker therapy: an important consideration for both the patient and the physician. Urology 2002; 59 Suppl. 2A: 7-11
78. Leliefeld HH, Stoevelaar HJ, McDonnell J. Sexual function before and after various treatments for symptomatic benign prostatic hyperplasia. BJU Int 2002; 89: 208-13
79. Sairam K, Kulinskaya E, McNicholas TA, et al. Sildenafil influences lower urinatry tract symptoms. BJU Int 2002; 90: 836-9
80. Bautista OM, Kusek JW, Nyberg LM, et al. Study design of the Medical Therapy of Prostatic Symptoms trial. Control Clin Trials 2003 Apr; 24 (2): 224-43